Combining human and rat sequences in Her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity (Cancer Research (2010) 70, (119-28) DOI: 10.1158/0008-5472.CAN-09-2554);Combining human and rat sequences in Her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity

Cancer Research

Volumn 70, Issue 1, 2010, Pages 119-128

  Jacob, Jennifer B ^a   Quaglino, Elena ^b   Radkevich Brown, Olga ^a   Jones, Richard F ^a   Piechocki, Marie P ^a   Reyes, Joyce D ^a   Weise, Amy ^a   Amici, Augusto ^c   Wei, Wei Zen ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; HYBRID PROTEIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA IMMUNIZATION; DNA SEQUENCE; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 75149155673     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0036     Document Type: Erratum

References (36)

1. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999;4 suppl 12:51-9.
2. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996;15:254-64.
3. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-38.
4. Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 1994; 13:3302-11.
5. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12.
6. Kiessling R, Wei WZ, Herrmann F, et al. Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 2002;85:101-44.
7. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
8. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-49.
9. Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001;61:7196-203.
10. Ritter CA, Perez-Torres M, Rinehart C, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007;13:4909-19.
11. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-43.
12. Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. HER2/Neu (ErbB2) signaling to Rac1-1 is temporally and spatially modulated by transforming growth factor β. Cancer Res 2006;66:9591-600.
13. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-84.
14. Jacob JB, Kong YM, Nalbantoglu I, Snower DP, Wei WZ. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J Immunol 2009;182:5873-81.
15. Radkevich-Brown O, Jacob J, Kershaw M, Wei WZ. Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice. Cancer Res 2009;69:212-8.
16. Miller S, McRae BL, Vanderlugt C, Nikcevich KM, Ope JG, Karpus WJ. Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating disease. Immunol Rev 1995; 144:225.
17. Swanborg RH, Stepaniak JA. Experimental autoimmune encephalomyelitis in the rat. In: Coligan JE, Kruisbeek AM, Margulies DH, editors. Current protocols in immunology. New York: John Wiley & Sons Inc.; 1996, p. 15.2.1-2.4.
18. Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997; 61:1861-78.
19. Christadoss P, Lindstrom JM, Talal N, Duvic CR, Kalantri A, Shenoy M. Immune response gene control of lymphocyte proliferation induced by acetylcholine receptor-specific helper factor derived from lymphocytes of myasthenic mice. J Immunol 1986;137:1845-9.
20. Christadoss P, Poussin M, Deng C. Animal models of myasthenia gravis. Clin Immunol 2000;94:75-87.
21. Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24:4582-5.
22. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008;9:776-88.
23. Jacob J, Radkevich O, Forni G, et al. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 2006;240:96-106.
24. Whittington PJ, Piechocki MP, Heng HH, et al. DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies. Cancer Res 2008;68:7502-11.
25. Piechocki MP, Ho YS, Pilon S, Wei WZ. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 2003;171:5787-94.
26. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A 1991;88:8691-5.
27. Bacus SS, Stancovski I, Huberman E, et al. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res 1992;52:2580-9.
28. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60.
29. Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 1984;312:545-8.
30. Mahoney KH, Miller BE, Heppner GH. FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor-associated macrophages from metastatic and nonmetastatic mouse mammary tumors. J Leukoc Biol 1985;38:573-85.
31. Wei WZ, Shi WP, Galy A, et al. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999;81:748-54.
32. Piechocki MP, Pilon SA, Wei WZ. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 2001;167:3367-74.
33. King BL, Carter D, Foellmer HG, Kacinski BM. Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. Am J Pathol 1992;140:23-31.
34. Jacob JB, Kong YM, Meroueh C, et al. Control of Her-2 tumor immunity and thyroid autoimmunity by MHC, regulatory T cells. Cancer Res 2007;67:7020-7.
35. Piechocki MP, Pilon SA, Wei WZ. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods 2002;259:33-42.
36. Rolla S, Marchini C, Malinarich S, et al. Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain. Hum Gene Ther 2008;19:229-40.